P2921
Monoclonal Anti-Protein A antibody produced in mouse
clone SPA-27, ascites fluid
Synonym(s):
Monoclonal Anti-Protein A
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
NACRES:
NA.46
UNSPSC Code:
12352203
Conjugate:
unconjugated
Clone:
SPA-27, monoclonal
Application:
ELISA (i), ICC, WB
Citations:
19
biological source
mouse
conjugate
unconjugated
antibody form
ascites fluid
antibody product type
primary antibodies
clone
SPA-27, monoclonal
contains
15 mM sodium azide
technique(s)
immunocytochemistry: suitable, indirect ELISA: 1:20,000, western blot: suitable
isotype
IgG1
shipped in
dry ice
storage temp.
−20°C
target post-translational modification
unmodified
Quality Level
General description
Protein A is a 42 kDa single chain polypeptide isolated from the cell wall of Staphylococcus aureus Cowan I strain.
Immunogen
protein A from Cowan I strain of Staphylococcus aureus.
Application
Monoclonal Anti-Protein A antibody produced in mouse has been used in enzyme-linked immunosorbent assay (ELISA). It has also been used in western blot and dot blot analyses.
Biochem/physiol Actions
Protein A is considered as a universal reagent in biochemistry and immunology, due to its affinity for the Fc region of many mammalian immunoglobulins. It is used for different applications such as purification of immunoglobulins by affinity chromatography, cell surface studies, radioimmunoassay (RIA), enzyme immunoassay (EIA), immunoprecipitations and many other procedures. It can be used in these methods either in its native form or conjugated to various markers.
Specific for Protein A and shows no cross-reactivity with Protein G. Reacts with free Protein A or IgG bound Protein A and does not interfere with the Fc binding activity of Protein A.
Physical form
Monoclonal Anti-Protein A antibody produced in mouse is provided as ascites fluid with 15 mM sodium azide.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Storage Class
10 - Combustible liquids
wgk
nwg
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
动植物来源生物产品
常规特殊物品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Stephanie Marroquin et al.
Infection and immunity, 87(5) (2019-03-06)
Numerous factors have, to date, been identified as playing a role in the regulation of Agr activity in Staphylococcus aureus, including transcription factors, antisense RNAs, and host elements. Herein we investigated the product of SAUSA300_1984 (termed MroQ), a transmembrane Abi-domain/M79
Matthew B Frankel et al.
Molecular microbiology, 78(1), 238-252 (2010-10-07)
The human pathogen Staphylococcus aureus requires cell wall anchored surface proteins to cause disease. During cell division, surface proteins with YSIRK signal peptides are secreted into the cross-wall, a layer of newly synthesized peptidoglycan between separating daughter cells. The molecular
Dane Vassiliadis et al.
BMC genomics, 20(1), 251-251 (2019-03-30)
Optimal glucose metabolism is central to the growth and development of cells. In microbial eukaryotes, carbon catabolite repression (CCR) mediates the preferential utilization of glucose, primarily by repressing alternate carbon source utilization. In fission yeast, CCR is mediated by transcriptional
Pernille Koefoed-Nielsen et al.
Journal of clinical apheresis, 32(3), 163-169 (2016-06-04)
Transplanting immunized patients requires immunological monitoring in the pretransplant phase to follow reduction of donor specific HLA antibodies (DSA) after Staphylococcus aureus protein A (SPA) immunoadsorption (IA) or therapeutic plasma exchange followed by IVIG and Rituximab administration. Pretreatment aims to
Comparison of protein A affinity sorbents III. Life time study
Hahn R, et al.
Journal of Chromatography A, 1102(1-2), 224-231 (2006)
Related Content
Instructions
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service